Delivery Order SPE2DR25D2010-SPE2DR26F4ZFB
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,022.29 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens on October 28, 2025, with completion scheduled for October 29, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a small-value pharmaceutical procurement for federal medical supply needs. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections with a ceiling value of $2,214.84. This is a firm fixed-price delivery order with an ultimate completion date of December 9, 2025, and carries no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 ml pens with a ceiling value of $2,726.72. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and represents a non-set-aside competitive award. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order from the Defense Logistics Agency (DLA) on November 18, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens valued at $1,570.16. This competitively awarded, firm fixed-price delivery order is scheduled for completion by November 19, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no...
- On December 1, 2025, the Defense Logistics Agency awarded a delivery order valued at $26,609.49 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 ml pen injectors. This firm fixed-price delivery order, with an ultimate completion date of December 2, 2025, represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist used in diabetes and...
- The Defense Logistics Agency awarded a delivery order valued at $11,161.15 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on August 5, 2025, with completion scheduled for August 6, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively through an open procurement process. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $1,525.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens. The contract, which is a child order under a larger vehicle, carries an ultimate completion date of August 14, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound 5 mg/0.5 mL pens in 0.5 mL quantities, with a ceiling value of $22,471.17. This firm fixed-price delivery order, with an ultimate completion date of July 31, 2025, represents a competitively awarded, non-set-aside contract. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing this work at its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens totaling $8,026.30 on September 25, 2025, with completion expected by September 26, 2025. This firm fixed-price, competitively awarded delivery order represents a single transaction under AmerisourceBergen's broader pharmaceutical supply arrangement with the federal government. The product will be delivered to AmerisourceBergen's distribution facility in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,458.10 on December 5, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injections. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's distribution facility in Conshohocken, Pennsylvania, with an ultimate...
- SPE2DR25D2010Indefinite Delivery Contract
- SPE2DR25D2010-SPE2DR26F4ZFBDelivery Order
The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Zepbound 10 mg/0.5 mL pens with a ceiling value of $7,462.47. This is a firm fixed-price delivery order with an ultimate completion date of December 11, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as one of the nation's largest pharmaceutical distributors. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military and federal healthcare systems. The IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare customers worldwide. Zepbound is a GLP-1 receptor agonist used for weight management, and this order reflects the company's role in providing specialized medications across multiple therapeutic domains to support federal medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.5k | 12/9/25 |